{"id":"W3082576563","doi":"10.1097/qai.0000000000002466","title":"Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials","year":2020,"lang":"en","type":"article","venue":"JAIDS Journal of Acquired Immune Deficiency Syndromes","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":149,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Torii Pharmaceutical; ViiV Healthcare; Gilead Sciences; GlaxoSmithKline","keywords":"Rilpivirine; Medicine; Fluid-attenuated inversion recovery; Atlas (anatomy); Clinical trial; Antiretroviral therapy; Human immunodeficiency virus (HIV); Internal medicine; Medical physics; Virology; Radiology; Viral load; Magnetic resonance imaging","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002315437,0.0003715042,0.002621279,0.0009145017,0.0001603682,0.00005428576,0.0002457328,0.0001093433,0.0001293926],"category_scores_gemma":[0.001799781,0.0002555471,0.0009509235,0.002037405,0.0001490212,0.0003099408,0.00005826641,0.00013477,0.000009375939],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009906197,"about_ca_system_score_gemma":0.0002984383,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001745775,"about_ca_topic_score_gemma":0.000002071595,"domain_scores_codex":[0.9963273,0.0001979162,0.002075835,0.0003557937,0.0005688889,0.0004741974],"domain_scores_gemma":[0.9966962,0.00072359,0.001584884,0.0002763206,0.0004831018,0.0002359081],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.03312217,0.009451658,0.08068505,0.001707576,0.06991189,0.002263291,0.02682423,0.0009307959,0.552162,0.000429381,0.01046118,0.2120508],"study_design_scores_gemma":[0.2484103,0.04045603,0.1639892,0.004427911,0.09072145,0.003653119,0.02745708,0.02694028,0.3681145,0.0009243548,0.02083141,0.004074386],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9804086,0.009783404,0.004430018,0.004248283,0.000201956,0.0006999085,0.00005967302,0.00003920346,0.0001289401],"genre_scores_gemma":[0.9923581,0.001563906,0.004010236,0.0000980554,0.00007008485,0.00001999968,0.00005621732,0.00004698739,0.00177636],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2152881,"threshold_uncertainty_score":0.9999897,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04886990321091243,"score_gpt":0.3219848877726683,"score_spread":0.2731149845617558,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}